Eris Bionxt Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 14.31 Cr
as on 15-12-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 73.50 Cr
as on 15-12-2024
- Revenue %
(FY 2022)
- Ebitda
- Net Worth 99.68%
(FY 2022)
- Total Assets 154.56%
(FY 2022)
About Eris Bionxt
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 14.31 Cr.
The company has closed loans amounting to ₹73.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Eris Bionxt Private Limited India are Kaushal Shah as CEO and Sanad Gajwani as Company Secretary. Kaushal Shah, Inderjeet Negi, and Sachin Shah serve as directors at the Company.
- CIN/LLPIN
U24299MP2020PTC051505
- Company No.
051505
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2020
- Date of AGM
11 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Raisen, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Eris Bionxt?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kaushal Shah | CEO | 13-Dec-2024 | Current |
| Sanad Gajwani | Company Secretary | 13-Dec-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushal Shah  | Director | 13-Sep-2024 | Current |
| Inderjeet Negi | Director | 13-Sep-2024 | Current |
| Sachin Shah | Director | 13-Sep-2024 | Current |
Financial Performance and Corporate Structure Insights of Eris Bionxt.
Chemman Labs Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 99.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Eris Bionxt?
In 2022, Eris Bionxt had a promoter holding of 20.44% and a public holding of 79.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eris Lifesciences LimitedActive 17 years 10 monthsKaushal Shah and Inderjeet Negi are mutual person
- Eris Healthcare Private LimitedActive 11 years 6 months
Kaushal Shah, Inderjeet Negi and 1 more are mutual person
Eris Therapeutics LimitedActive 3 years 5 monthsKaushal Shah, Inderjeet Negi and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Sep 2022 | ₹47.50 Cr | Satisfied |
Karnataka Bank Ltd. Creation Date: 03 May 2021 | ₹26.00 Cr | Satisfied |
How Many Employees Work at Eris Bionxt?
Eris Bionxt has a workforce of 116 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eris Bionxt, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eris Bionxt's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
